Abstract
Acquired severe aplastic anemia (SAA) is a life-threatening bone marrow failure syndrome. Immunosuppressive therapy (IST) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) are the main treatments for acquired SAA. Matched sibling donor (MSD)-hematopoietic stem cell transplantation (HSCT) is the best treatment for acquired SAA patients who are younger than 40 years old. Outcomes of unrelated donor (URD)-HSCT, haploidentical hematopoietic stem cell transplantation (haplo-HSCT) and umbilical cord blood transplantation (UCBT) have improved in the recent decade, and provide more options with respect to the clinical treatment of acquired SAA. In order to improve clinicians′ understanding of allo-HSCT for acquired SAA, this article reviews the research progress of acquired SAA treated by allo-HSCT in recent years. Key words: Anemia, aplastic; Hematopoietic stem cell transplantation; Donor selection; Transplantation conditioning; Graft vs host disease; Transplantation, haploidentical; Cord blood stem cell transplantation
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
